Saturday 17 October 2026
Export BOLT’s income statement to Excel — free account
Bolt Biotherapeutics, Inc.
BOLT Healthcare Biotechnology
In the quarter to June 2026, revenue fell 99.7%, EPS fell 2.47%, free cash flow grew 38.9% and total debt fell 14.3%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
4.06
0.18
−4.25%
Follow BOLT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
1 | 4 | 4 | 3 |
| (81.97%) | (79.75%) | (88.79%) | (111.65%) | ||
| (48.95%) | (42.69%) | (44.19%) | (49.62%) | ||
ROIC |
(141.48%) | (119.22%) | (122.80%) | (143.75%) | |
Return on Tangible Assets |
(157.26%) | (144.67%) | (152.07%) | (216.60%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(24.09) | (20.83) | (20.56) | (18.23) | |
Free Cash Flow |
(46.23) | (38.96) | (34.55) | (30.82) | |
Capital Expenditures |
0.89 | 0.89 | (0.04) | 0.63 | |
| Other line items | |||||
Cash ROIC |
(53.96%) | (52.41%) | (55.49%) | (62.93%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
678.86% | 370.80% | 366.98% | 457.47% | |
Selling, General and Administrative Expense of Revenue |
281.52% | 179.27% | 196.46% | 248.38% | |
Share Based Compensation of Revenue |
56.27% | 36.15% | 40.28% | 54.15% | |
Operating CF/Net income |
1.10 | 1.19 | 1.17 | 1.09 | |
Depreciation/Fixed assets |
0.43 | 0.50 | 0.57 | 0.89 | |
Capex/Depreciation |
1.38 | 1.43 | (0.07) | 1.25 | |
Revenue per Share |
2.71 | 4.12 | 3.87 | 2.78 | |
Operating CF per Share |
(24.56) | (21.31) | (20.54) | (18.60) | |
Capex per Share |
0.46 | 0.48 | (0.02) | 0.37 | |
Capex to Sales |
(0.17) | (0.12) | 0.01 | (0.13) |
Columns are period end dates